Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Rentokil Initial plc about the lead plaintiff deadline for a class action lawsuit related to alleged misleading statements and execution challenges during the integration of Terminix [1][5]. Group 1: Class Action Details - Investors who purchased Rentokil ADSs between December 1, 2023, and September 10, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 27, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Allegations Against Rentokil - The lawsuit claims that Rentokil made false and misleading statements regarding the integration of Terminix, including disruptions and execution challenges that negatively impacted business operations and organic revenue growth in North America [5]. - Specific allegations include that Rentokil and Terminix remained separate businesses and that the integration plan was imperiled due to these challenges [5].

Core Viewpoint - Rentokil Initial plc is facing a class action lawsuit due to alleged misleading statements and failures to disclose critical information regarding its integration of Terminix Global Holdings, which negatively impacted its business performance and stock price [3][4][5][6]. Group 1: Class Action Details - The class action represents investors who purchased Rentokil securities between December 1, 2023, and September 10, 2024, with a deadline for filing a lead plaintiff motion set for January 27, 2025 [1]. - The lawsuit claims that Rentokil made false statements and failed to disclose significant integration challenges with Terminix, jeopardizing its business operations [4]. Group 2: Financial Impact - Rentokil's organic revenue growth in North America was reported at only 1.5% year-over-year on April 18, 2024, significantly below the company's earlier guidance of 2% for Q1 and 2% to 4% for the full year [5]. - Following the disappointing revenue growth announcement, Rentokil's American Depositary Shares (ADS) price dropped by more than 9% [5]. - An unscheduled trading update on September 11, 2024, forecasted just 1% organic revenue growth for the second half of 2024, leading to a further decline of over 21% in the ADS price [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rentokil Initial plc due to alleged violations of federal securities laws, particularly concerning misleading statements about the integration of Terminix and its impact on the company's performance [2][4]. Group 1: Allegations Against Rentokil - The complaint alleges that Rentokil and its executives made false or misleading statements regarding the integration of Terminix, which faced significant execution challenges [4]. - Specific issues cited include disruption during the early integration pilots, ongoing execution challenges, and the failure to integrate Terminix, which negatively impacted organic revenue growth in North America [4]. - The allegations suggest that Rentokil's positive statements about its business and prospects lacked a reasonable basis and were materially false [4]. Group 2: Financial Performance and Market Reaction - On April 18, 2024, Rentokil reported only 1.5% organic revenue growth in North America for Q1 2024, below the guidance of 2%, leading to a 9% drop in the stock price [5]. - A subsequent trading update on September 11, 2024, revealed an expected 1% organic revenue growth for the second half of 2024, significantly lower than prior guidance, resulting in a 21% decline in stock price [6]. - The CEO and CFO acknowledged execution challenges during a conference call, indicating that the integration efforts had not been successful and that the businesses remained largely separate [6].

Core Viewpoint - Rentokil Initial plc is facing legal action due to alleged misleading statements regarding its financial performance and integration challenges with Terminix, leading to significant stock price declines during the class period [1][5]. Financial Performance - In Q1 2024, Rentokil reported organic revenue growth in North America of only 1.5% year-over-year, which was below the company's guidance of 2% for the quarter and 2% to 4% for the full year [3]. - Following the Q1 results announcement, Rentokil's ADS price dropped 9%, from $28.25 on April 17, 2024, to $25.61 on April 18, 2024 [3]. - On September 11, 2024, Rentokil revised its North American organic revenue growth forecast for the second half of the year down to 1%, significantly below previous guidance [4]. - The share price fell by approximately 21% on the news of the revised forecast, from $31.60 on September 10, 2024, to $24.95 on September 11, 2024 [4]. Integration Challenges - The lawsuit claims that Rentokil faced significant disruptions and execution challenges during the integration of Terminix, which negatively impacted its business operations and revenue growth [5]. - CEO Andy Ransom acknowledged that the integration process was complex and far from complete, attributing issues to internal execution failures rather than market conditions [4]. - Analysts from UBS and Deutsche Bank expressed concerns over Rentokil's credibility and lowered profit forecasts, predicting prolonged integration challenges and slowed growth through 2026 [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Rentokil Initial plc regarding a class action lawsuit due to alleged misleading statements and execution challenges related to the integration of Terminix [1][3]. Group 1: Allegations - The complaint alleges that during the class period from December 1, 2023, to September 10, 2024, Rentokil made materially false and misleading statements [3]. - Specific allegations include disruption in early pilots of the Terminix integration, significant self-inflicted execution challenges, and the failure to integrate Terminix, which negatively impacted organic revenue growth in North America [3]. - The lawsuit claims that Rentokil and Terminix remained separate businesses and that the positive statements made by the defendants lacked a reasonable basis [3]. Group 2: Class Action Details - Shareholders who purchased shares of Rentokil during the specified class period are encouraged to register for the class action, with a deadline of January 27, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - Shareholders of Rentokil Initial plc (RTO) who have incurred financial losses are encouraged to reach out to Levi & Korsinsky regarding a pending class action lawsuit [1] Group 1 - The class action is aimed at addressing the grievances of shareholders who lost money on their investments in Rentokil Initial plc [1] - Levi & Korsinsky is the law firm representing the interests of the affected shareholders [1]

Core Viewpoint - Rentokil Initial Plc stockholders are presented with an opportunity to lead a class action lawsuit against the company, indicating potential legal challenges ahead for the firm [1] Group 1 - The announcement is made by Bronstein, Gewirtz and Grossman, LLC, a law firm that specializes in securities class action lawsuits [1] - The class action lawsuit is likely a response to alleged misconduct or misrepresentation by Rentokil Initial Plc, which could impact investor confidence [1] - Stockholders are encouraged to participate in the lawsuit, suggesting a significant level of concern among investors regarding the company's practices [1]

Core Viewpoint - Investors in Rentokil Initial plc are encouraged to contact Levi & Korsinsky before January 27, 2025, to discuss their rights regarding potential claims [1] Group 1 - The deadline for investors to reach out is set for January 27, 2025 [1] - The communication is aimed at discussing rights related to potential claims against Rentokil Initial plc [1]

RTO FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rentokil Initial plc Investors to Secure Counsel Before Important January 27 Deadline in Securities Class Action – RTO ...

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 27, 2025 in Rentokil Initial plc Lawsuit - RTO ...